Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
59
Altimmune Inc News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 43.90 | -0.49% |
| CAC 40 | 8,084.51 | 61.82 | 0.77% |
| DAX 40 | 24,279.22 | 149.08 | 0.62% |
| Dow JONES (US) | 48,507.47 | 449.72 | 0.94% |
| FTSE 100 | 9,691.42 | 35.89 | 0.37% |
| HKSE | 25,530.51 | 10.27 | -0.04% |
| NASDAQ | 23,379.47 | 274.69 | -1.16% |
| Nikkei 225 | 50,148.82 | 453.98 | -0.90% |
| NZX 50 Index | 13,395.87 | 24.81 | 0.19% |
| S&P 500 | 6,856.84 | 29.84 | -0.43% |
| S&P/ASX 200 | 8,592.00 | 39.50 | -0.46% |
| SSE Composite Index | 3,873.32 | 27.18 | -0.70% |